留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

炎症生物标志物对肝癌肝移植预后的预测作用

牛义善 曾强

牛义善, 曾强. 炎症生物标志物对肝癌肝移植预后的预测作用[J]. 器官移植, 2022, 13(1): 49-54. doi: 10.3969/j.issn.1674-7445.2022.01.008
引用本文: 牛义善, 曾强. 炎症生物标志物对肝癌肝移植预后的预测作用[J]. 器官移植, 2022, 13(1): 49-54. doi: 10.3969/j.issn.1674-7445.2022.01.008
Niu Yishan, Zeng Qiang. Predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 49-54. doi: 10.3969/j.issn.1674-7445.2022.01.008
Citation: Niu Yishan, Zeng Qiang. Predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 49-54. doi: 10.3969/j.issn.1674-7445.2022.01.008

炎症生物标志物对肝癌肝移植预后的预测作用

doi: 10.3969/j.issn.1674-7445.2022.01.008
基金项目: 

河北省2020年度引进留学人员资助项目 C20200346

详细信息
    作者简介:

    牛义善,男,1997年生,硕士研究生,研究方向为肝移植,Email:1749193537@qq.com

    曾强,博士研究生导师。河北医科大学第三医院肝胆外科副主任医师、副教授。美国MD Anderson Cancer Center访问学者。长期从事肝胆外科及肝移植工作,并开展了肝移植术后管理及免疫耐受方面的科学研究。兼任中华医学会器官移植学分会青年委员、中国医疗保健交流促进会肝脏移植分会代谢管理学组委员、中国抗癌学会腔镜与机器人外科学分会委员、中国微循环学会肝脏微循环专业委员会委员、《器官移植》杂志通讯编委。主持参与多项肝移植方面的研究课题,并荣获河北省卫生厅科技进步一等奖,发表中华系列论文及SCI论文十余篇

    通讯作者:

    曾强,Email:zengqiang457@qq.com

  • 中图分类号: R617, R364.5

Predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma

More Information
  • 摘要: 肝细胞癌(肝癌)肝移植术后肿瘤复发是影响受者远期生存的主要问题。术前精确评估和合理选择移植受者是影响肝癌移植受者远期预后的关键因素。中性粒细胞、淋巴细胞、C-反应蛋白、血小板、纤维蛋白原(FIB)等是提示机体炎症反应的生物学指标,多项研究发现此类生物学指标不仅可以代表炎症反应,也可将其整合以用于预测肝癌肝移植术后肿瘤复发和受者长期生存率,这其中主要包括中性粒细胞/淋巴细胞比值(NLR)、格拉斯哥预后评分(GPS)、FIB、血小板/淋巴细胞比值(PLR)、预后营养指数(PNI)等。本文就炎症生物标志物对肝癌肝移植预后的预测作用的研究进展做一综述。

     

  • [1] CITORES MJ, LUCENA JL, DE LA FUENTE S, et al. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation[J]. World J Hepatol, 2019, 11(1): 50-64. DOI: 10.4254/wjh.v11.i1.50.
    [2] SIMSEK C, KIM A, MA M, et al. Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series[J]. Hepatoma Res, 2020, 6: 11. DOI: 10.20517/2394-5079.2019.51.
    [3] SALEH M, KHALIL M, ABDELLATEIF MS, et al. Role of matrix metalloproteinase MMP-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP-1) in the clinical progression of pediatric acute lymphoblastic leukemia[J]. Hematology, 2021, 26(1): 758-768. DOI: 10.1080/16078454.2021.1978763.
    [4] MIETHE C, TORRES L, ZAMORA M, et al. Inhibition of PI3K/Akt and ERK signaling decreases visfatin-induced invasion in liver cancer cells[J]. Horm Mol Biol Clin Investig, 2021, 42(4): 357-366. DOI: 10.1515/hmbci-2021-0011.
    [5] WAIGEL S, RENDON BE, LAMONT G, et al. MIF inhibition reverts the gene expression profile of human melanoma cell line-induced MDSCs to normal monocytes[J]. Genom Data, 2016, 7: 240-242. DOI: 10.1016/j.gdata.2015.12.025.
    [6] NYLEC M, DERBISZ K, CHRZĄSZCZ P, et al. Preoperative neutrophil-to-lymphocyte ratio as an independent predictor of 1-year graft loss and mortality after orthotopic liver transplantation[J]. Transplant Proc, 2020, 52(8): 2472-2476. DOI: 10.1016/j.transproceed.2020.03.036.
    [7] NAGAI S, YOSHIDA A, KOHNO K, et al. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation[J]. Hepatology, 2014, 59(1): 35-45. DOI: 10.1002/hep.26536.
    [8] FIGIEL W, GRĄT M, NIEWIŃSKI G, et al. Applicability of common inflammatory markers in diagnosing infections in early period after liver transplantation in intensive care setting[J]. Sci Rep, 2020, 10(1): 3918. DOI: 10.1038/s41598-020-60936-0.
    [9] HARIMOTO N, YOSHIZUMI T, SHIMAGAKI T, et al. Inflammation-based prognostic score in patients with living donor liver transplantation for hepatocellular carcinoma[J]. Anticancer Res, 2016, 36(10): 5537-5542. DOI: 10.21873/anticanres.11137.
    [10] HARIMOTO N, SHIRABE K, NAKAGAWARA H, et al. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio[J]. Transplantation, 2013, 96(11): 1008-1012. DOI: 10.1097/TP.0b013e3182a53f2b.
    [11] WANG GY, YANG Y, LI H, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J]. PLoS One, 2011, 6(9): e25295. DOI: 10.1371/journal.pone.0025295.
    [12] REN A, LI Z, ZHANG X, et al. Inflammation-based prognostic scores in patients with hepatitis B virus-related hepatocellular carcinoma after liver transplantation[J]. J Hepatocell Carcinoma, 2020, 7: 101-106. DOI: 10.2147/JHC.S259992.
    [13] MEISCHL T, RASOUL-ROCKENSCHAUB S, GYÖRI G, et al. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation[J]. PLoS One, 2019, 14(5): e0216677. DOI: 10.1371/journal.pone.0216677.
    [14] ABE T, TASHIRO H, HATTORI M, et al. Prediction of long-term survival by using the Glasgow prognostic score in patients with hepatocellular carcinoma after liver transplantation[J]. Hepatol Res, 2016, 46(7): 622-633. DOI: 10.1111/hepr.12597.
    [15] KALTENBORN A, SCHREM H, REICHERT B, et al. The Glasgow prognostic score and its variants predict mortality in living donor but not in deceased donor liver transplantation for hepatocellular carcinoma: a double-center validation study[J]. Hepatol Res, 2017, 47(8): 783-792. DOI: 10.1111/hepr.12818.
    [16] LI Y, LI Z, DENG K, et al. Fibrinogen/lymphocyte count ratio can be used as a new indicator of prognosis in patients with hepatocellular carcinoma after radical resection[J]. Cancer Manag Res, 2020, 12: 9057-9066. DOI: 10.2147/CMAR.S266653.
    [17] PAVLOVIC N, RANI B, GERWINS P, et al. Platelets as key factors in hepatocellular carcinoma[J]. Cancers (Basel), 2019, 11(7): 1022. DOI: 10.3390/cancers11071022.
    [18] PALACIOS-ACEDO AL, MÈGE D, CRESCENCE L, et al. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy[J]. Front Immunol, 2019, 10: 1805. DOI: 10.3389/fimmu.2019.01805.
    [19] DAI T, PENG L, LIN G, et al. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma[J]. J Gastrointest Oncol, 2019, 10(6): 1049-1063. DOI: 10.21037/jgo.2019.09.11.
    [20] WANG GY, JIANG N, YI HM, et al. Pretransplant elevated plasma fibrinogen level is a novel prognostic predictor for hepatocellular carcinoma recurrence and patient survival following liver transplantation[J]. Ann Transplant, 2016, 21: 125-130. DOI: 10.12659/aot.895416.
    [21] HUANG G, JIANG H, LIN Y, et al. Prognostic value of plasma fibrinogen in hepatocellular carcinoma: a Meta-analysis[J]. Cancer Manag Res, 2018, 10: 5027-5041. DOI: 10.2147/CMAR.S175780.
    [22] FU SJ, JI F, HAN M, et al. Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation[J]. Oncotarget, 2017, 8(3): 4301-4312. DOI: 10.18632/oncotarget.13804.
    [23] AUGUSTINE TN. The aegis: platelets as biomarkers of tumor progression[J]. Biomark Med, 2020, 14(7): 573-585. DOI: 10.2217/bmm-2019-0514.
    [24] BRAUN A, ANDERS HJ, GUDERMANN T, et al. Platelet-cancer interplay: molecular mechanisms and new therapeutic avenues[J]. Front Oncol, 2021, 11: 665534. DOI: 10.3389/fonc.2021.665534.
    [25] HAN S. Possible roles of platelets in liver transplantation: regeneration and cancer recurrence[J]. Anesth Pain Med (Seoul), 2021, 16(3): 225-231. DOI: 10.17085/apm.21063.
    [26] HAN S, LEE S, YANG JD, et al. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation[J]. Liver Transpl, 2018, 24(1): 44-55. DOI: 10.1002/lt.24961.
    [27] XIA W, KE Q, WANG Y, et al. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation[J]. World J Surg Oncol, 2015, 13: 60. DOI: 10.1186/s12957-015-0472-2.
    [28] LIU Y, SHI M, CHEN S, et al. Intermediate stage hepatocellular carcinoma: comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization[J]. J Cancer Res Ther, 2021, 17(3): 740-748. DOI: 10.4103/jcrt.jcrt_29_21.
    [29] WANG D, BAI N, HU X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC[J]. PeerJ, 2019, 7: e7132. DOI: 10.7717/peerj.7132.
    [30] LAI Q, MELANDRO F, LARGHI LAUREIRO Z, et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: a systematic review and Meta-analysis[J]. World J Gastroenterol, 2018, 24(15): 1658-1665. DOI: 10.3748/wjg.v24.i15.1658.
    [31] ISMAEL MN, FORDE J, MILLA E, et al. Utility of inflammatory markers in predicting hepatocellular carcinoma survival after liver transplantation[J]. Biomed Res Int, 2019: 7284040. DOI: 10.1155/2019/7284040.
    [32] XIA W, KE Q, GUO H, et al. Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio[J]. BMC Cancer, 2017, 17(1): 14. DOI: 10.1186/s12885-016-3028-0.
    [33] WANG Z, WANG J, WANG P. The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: a Meta-analysis of observational studies[J]. PLoS One, 2018, 13(10): e0202987. DOI: 10.1371/journal.pone.0202987.
    [34] TANEMURA A, MIZUNO S, HAYASAKI A, et al. Onodera's prognostic nutritional index is a strong prognostic indicator for patients with hepatocellular carcinoma after initial hepatectomy, especially patients with preserved liver function[J]. BMC Surg, 2020, 20(1): 261. DOI: 10.1186/s12893-020-00917-2.
    [35] JI F, LIANG Y, FU S, et al. Prognostic value of combined preoperative prognostic nutritional index and body mass index in HCC after hepatectomy[J]. HPB (Oxford), 2017, 19(8): 695-705. DOI: 10.1016/j.hpb.2017.04.008.
    [36] MIN JY, WOO A, CHAE MS, et al. Predictive impact of modified-prognostic nutritional index for acute kidney injury within 1-week after living donor liver transplantation[J]. Int J Med Sci, 2020, 17(1): 82-88. DOI: 10.7150/ijms.39014.
    [37] PRAVISANI R, MOCCHEGIANI F, ISOLA M, et al. Postoperative trends and prognostic values of inflammatory and nutritional biomarkers after liver transplantation for hepatocellular carcinoma[J]. Cancers (Basel), 2021, 13(3): 513. DOI: 10.3390/cancers13030513.
    [38] LIU C, LI L, LU WS, et al. Neutrophil-lymphocyte ratio plus prognostic nutritional index predicts the outcomes of patients with unresectable hepatocellular carcinoma after transarterial chemoembolization[J]. Sci Rep, 2017, 7(1): 13873. DOI: 10.1038/s41598-017-13239-w.
  • 加载中
图(1)
计量
  • 文章访问数:  256
  • HTML全文浏览量:  72
  • PDF下载量:  59
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-24
  • 网络出版日期:  2022-01-12
  • 刊出日期:  2022-01-15

目录

    /

    返回文章
    返回